Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tocilizumab in refractory Caucasian Takayasu's arteritis, a multicenter study of 54 patients and literature review

  • Prieto-Peña, Diana
  • Bernabeu, Pilar
  • Vela, Paloma|||0000-0001-8566-5172
  • Narváez, Javier|||0000-0002-1614-8064
  • Fernández-López, Jesús C.
  • Freire-González, Mercedes
  • González-Álvarez, Beatriz
  • Solans, Roser|||0000-0002-0058-1293
  • Callejas Rubio, Jose Luis|||0000-0002-1653-0087
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Fernández-Díaz, Carlos
  • Rubio, Esteban
  • García-Morillo, Salvador
  • Minguez, Mauricio
  • Fernández-Carballido, Cristina|||0000-0002-0910-4944
  • Miguel, Eugenio de|||0000-0001-5146-1964
  • Melchor, Sheila
  • Salgado, Eva
  • Bravo, Beatriz
  • Romero-Yuste, Susana
  • Salvatierra, Juan
  • Hidalgo, Cristina
  • Manrique, Sara
  • Romero-Gómez, Carlos
  • Moya, Patricia|||0000-0001-8339-5420
  • Álvarez-Rivas, Noelia
  • Mendizabal, Javier
  • Ortiz Sanjuán, Francisco
  • Pérez de Pedro, Iván
  • Alonso-Valdivielso, José L.|||0000-0002-1862-6883
  • Perez-Sanchez, Laura
  • Roldán, Rosa
  • Fernandez-Llanio, Nagore
  • Gómez de la Torre, Ricardo
  • Suarez, Silvia
  • Montesa Cabrera, María Jesús
  • Delgado Sánchez, Mónica
  • Loricera, Javier|||0000-0003-4754-0277
  • Atienza-Mateo, Belén|||0000-0001-7119-0786
  • Castañeda, Santos|||0000-0002-7748-853X
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
  • Blanco, Ricardo|||0000-0003-2344-2285
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ and 31 (57.4%) on TCZ: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases, multicentre study of 80 patients

  • Martín-Varillas, José Luis|||0000-0001-6147-6633
  • Sánchez Bilbao, Lara
  • Calvo-Río, Vanesa
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Hernanz, Inés
  • Gallego-Flores, Adela
  • Beltran Catalan, Emma|||0000-0001-8070-6916
  • Castro-Oreiro, Sonia
  • Fanlo, Patricia
  • Garcia Martos, Alvaro
  • Torre, Ignacio
  • Cordero-Coma, Miguel
  • De Dios, Juan Ramon
  • García Aparicio, Ángel
  • Hernández-Garfella, Marisa
  • Sánchez-Andrade, Amalia
  • García-Valle, Andrea
  • Maiz, Olga|||0000-0003-2900-9511
  • Miguélez, Roberto
  • Rodríguez-Montero, Sergio
  • Urruticoechea-Arana, A.
  • Veroz, Raúl
  • Conesa, Arantxa
  • Fernández-Carballido, Cristina|||0000-0002-0910-4944
  • Jovaní, Vega
  • Mondejar, Jose J.
  • Martínez González, Olga
  • Moya, Patricia|||0000-0001-8339-5420
  • Romero-Yuste, Susana
  • Rubio-Muñoz, Paula
  • Peña-Sainz-Pardo, Eva
  • Garijo-Bufort, Marta
  • Demetrio-Pablo, Rosalía
  • Hernández, José Luis|||0000-0002-6585-8847
  • Blanco, Ricardo|||0000-0003-2344-2285
Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility, A case-only study

  • Montes, Ariana
  • Perez-Pampin, Eva
  • Navarro-Sarabia, Federica
  • Moreira, Virginia
  • Rodríguez de la Serna, Arturo
  • Magallares López, Berta|||0000-0002-4691-2342
  • Vasilopoulos, Yiannis
  • Sarafidou, Theologia
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Ordóñez, María del Carmen
  • Narváez, Javier|||0000-0002-1614-8064
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Márquez, Ana|||0000-0001-9913-7688
  • Pascual-Salcedo, Dora
  • Joven, Beatriz
  • Carreira, Patrícia
  • Moreno Ramos, Manuel José|||0000-0003-3800-7382
  • Caliz, Rafael
  • Ferrer, Miguel Ángel
  • Garcia-Portales, Rosa
  • Blanco-García, F.J.|||0000-0001-9821-7635
  • Magro, César
  • Raya, Enrique
  • Valor, Lara
  • Alegre-Sancho, Juan José|||0000-0003-1641-0875
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Martín, Javier|||0000-0002-2202-0622
  • Plant, Darren
  • Isaacs, John
  • Morgan, Ann W.
  • Barton, Anne|||0000-0003-3316-2527
  • Wilson, Anthony G.
  • Gómez-Reino, Juan J.
  • Gonzalez, Antonio
Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). Methods: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (DAS28) and the European League Against Rheumatism (EULAR) response criteria. Results: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in DAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. Conclusions: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA.